svnt genscript cpasstm  (GenScript corporation)

Journal: Animals : an Open Access Journal from MDPI

Article Title: Bison, Elk, and Other Captive Wildlife Species Humoral Immune Responses against SARS-CoV-2

doi: 10.3390/ani14192829

Figure Lengend Snippet: Detection of SARS-CoV-2-specific antibodies against the N and S (RBD) proteins in ( A ) bison and ( B ) elk using commercial N (ID-Vet; orange bars) and sVNT (GenScript, Piscataway NJ, USA; blue bars) IgG ELISAs. The X -axis represents the number and percentage of serum samples by collection year and location that were positive in the sVNT and N-ELISAs; the Y -axis represents the percentage of SARS-CoV-2 antibody seropositivity.

Article Snippet: Out of 50 collected serum samples from 26 mammal species and 1523 fecal samples from 103 mammal species, none of the samples tested positive by sVNT (GenScript cPassTM, Piscataway NJ, USA) and PCR [ ].

Techniques:

Journal: Chemical Science

Article Title: Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives

doi: 10.1039/d2sc06665c

Figure Lengend Snippet: Illustration of the LF-sVNT protocol and example sensorgrams. (A) First cycle measuring the binding ability of RBD to ACE2 after neutralization. (B) Second cycle measuring the full binding ability of RBD without neutralization. Reproduced with permission from J. Clin. Microbiol. , 2021, 59 , e0019321, 10.1128/JCM.00193-21.

Article Snippet: Michiels et al. compared the sVNT commercial kit (GenScript cPassTM) with a live virus neutralization assay and Luminex multiplex immunoassay (MIA), and studied two different cohorts using these three methods.

Techniques: Binding Assay, Neutralization

Journal: bioRxiv

Article Title: SARS-CoV-2 exposure in wild white-tailed deer ( Odocoileus virginianus )

doi: 10.1101/2021.07.29.454326

Figure Lengend Snippet:

Article Snippet: Samples were tested using the species and isotype independent Genscript cPassTM surrogate virus neutralization test (sVNT) in an ELISA format.

Techniques: Virus, Neutralization

Journal: bioRxiv

Article Title: SARS-CoV-2 exposure in wild white-tailed deer ( Odocoileus virginianus )

doi: 10.1101/2021.07.29.454326

Figure Lengend Snippet: Serum samples were tested using the Genscript cPass™ surrogate virus neutralization test (sVNT).

Article Snippet: Samples were tested using the species and isotype independent Genscript cPassTM surrogate virus neutralization test (sVNT) in an ELISA format.

Techniques: Virus, Neutralization

Journal: Journal of Virological Methods

Article Title: Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2

doi: 10.1016/j.jviromet.2021.114228

Figure Lengend Snippet: Sensitivity of the different serological tests and cut-offs used based on the final serum panels. Values between brackets represent 95 % confidence intervals on the estimations.

Article Snippet: Here, we performed an independent evaluation of a commercially available surrogate virus neutralization test (sVNT, GenScript cPassTM) that can be done without biosafety level 3 containment in less than 2 h. When using the cVNT and a Luminex multiplex immunoassay (MIA) as reference, the sVNT obtained a sensitivity of 94 % (CI 90–96 %) on a panel of 317 immune sera that were obtained from hospitalized and mild COVID-19 cases from Belgium and a sensitivity of 88 % (CI 81–93 %) on a panel of 184 healthcare workers from the Democratic Republic of Congo.

Techniques: Luminex

Journal: Journal of Virological Methods

Article Title: Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2

doi: 10.1016/j.jviromet.2021.114228

Figure Lengend Snippet: Correlations between the percentage of inhibition measured by the surrogate viral neutralisation test (sVNT) and the log(dilution factors or signal-to-noise ratio) for the conventional viral neutralization test (cVNT) or the Luminex multiplex immunological assay (MIA) as calculated by the nonparametric Spearman correlation test (r s ). Seropositivity cut-off levels for the sVNT are indicated by the dashed grey lines at 20 or 30 % inhibition. Negative samples on the cVNT or MIA were not included in these figures.

Article Snippet: Here, we performed an independent evaluation of a commercially available surrogate virus neutralization test (sVNT, GenScript cPassTM) that can be done without biosafety level 3 containment in less than 2 h. When using the cVNT and a Luminex multiplex immunoassay (MIA) as reference, the sVNT obtained a sensitivity of 94 % (CI 90–96 %) on a panel of 317 immune sera that were obtained from hospitalized and mild COVID-19 cases from Belgium and a sensitivity of 88 % (CI 81–93 %) on a panel of 184 healthcare workers from the Democratic Republic of Congo.

Techniques: Inhibition, Neutralization, Luminex, Multiplex Assay